Limiting FDI in pharma is a retrograde step

Recent media reports indicate that the Department of Industrial Policy and Promotion (DIPP) is contemplating to modify the FDI policy in the brownfield sector of the pharmaceutical industry. This rethinking has probably been prompted by the following apprehensions as expressed in a ‘discussion paper’ earlier circulated by the DIPP: Oligopolistic market will be created with an adverse impact on ‘public health interest’: Indian pharmaceutical market (IPM) has over 23,000 players and around 60,000 brands.

Read Full Story>>